This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Multiple sclerosis (MS); neurology	IL-18	<p>Studies in mice suggest that inhibiting IL-18 signaling could help treat demyelinating diseases such as MS. In a mouse model of demyelinating disease, IL-18 deficiency resulted in delayed demyelination and faster remyelination compared with those in wild-type controls. Next steps include identifying the cellular mechanism by which IL-18 regulates myelination.</p> <p>GlaxoSmithKline plc's 1070806, a humanized mAb against IL-18, is in Phase I testing for metabolic disorders.</p> <p>SciBX 3(47); doi:10.1038/scibx.2010.1415 Published online Dec. 9, 2010</p>	Patent and licensing undisclosed	<p>Jha, S. <i>et al. J. Neurosci.</i>; published online Nov. 24, 2010; doi:10.1523/JNEUROSCI.4088-10.2010</p> <p>Contact: Jenny P.-Y. Ting, The University of North Carolina at Chapel Hill, Chapel Hill, N.C. e-mail: panyun@med.unc.edu</p>